Zobrazeno 1 - 10
of 642
pro vyhledávání: '"Dose-ranging study"'
Autor:
Miles C. Smith, Lalitha R. Belur, Andrea D. Karlen, Olivia Erlanson, Justin Furcich, Troy C. Lund, Davis Seelig, Kelley F. Kitto, Carolyn A. Fairbanks, Kwi Hye Kim, Nick Buss, R. Scott McIvor
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 32, Iss 1, Pp 101201- (2024)
Mucopolysaccharidosis type II (MPS II) is an X-linked recessive lysosomal disease caused by iduronate-2-sulfatase (IDS) deficiency, leading to accumulation of glycosaminoglycans (GAGs) and the emergence of progressive disease. Enzyme replacement ther
Externí odkaz:
https://doaj.org/article/a2a8c79881364444bb7633c2c34e66ec
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Mamadou Dramé, Bruce L. Innis, Joon Hyung Kim, Wayne Woo, Khuanchai Supparatpinyo, Anne Schuind, Bruno Salaun, Nan-Chang Chiu, Kao-Pin Hwang, Po-Yen Chen, Thanyawee Puthanakit, Jasur Danier, David W. Vaughn, Damien Friel, Cheng-Hsun Chiu, Li-Min Huang
Publikováno v:
The Pediatric Infectious Disease Journal
Supplemental Digital Content is available in the text.
Background: This phase 2 observer-blind, randomized, multicenter, dose-ranging study evaluated immunogenicity and safety of different formulations of an AS03-adjuvanted H5N1 influenza vaccin
Background: This phase 2 observer-blind, randomized, multicenter, dose-ranging study evaluated immunogenicity and safety of different formulations of an AS03-adjuvanted H5N1 influenza vaccin
Publikováno v:
Journal of Asthma. 59:1410-1419
Introduction: This manuscript describes a Phase II, dose-ranging, randomized, double-blind, placebo- and active-controlled, parallel-group study conducted to identify the appropriate dose of beclom...
Publikováno v:
International Journal of Chronic Obstructive Pulmonary Disease
Gary T Ferguson,1 Edward M Kerwin,2 Tara Rheault,3 Thomas Bengtsson,4 Kathleen Rickard3 1Pulmonary Research Institute of Southeast Michigan, Farmington Hills, MI, USA; 2Altitude Clinical Consulting, Medford, OR, USA; 3Verona Pharma, Plc, Raleigh, NC,
Publikováno v:
Statistical Methods in Medical Research. 30:1013-1025
In a drug development program, the efficacy and safety of multiple doses can be evaluated in patients through a phase 2b dose ranging study. With a demonstrated dose response in the trial, promising doses are identified. Their effectiveness then is f
Autor:
Prashant Kumar, Julie E Bines, Pim Velthof, Christopher Yallop, Ahd Hamidi, Sangeeta B. Joshi, Swathi R. Pullagurla, David B. Volkin, Alfred Luitjens, Menzo J. E. Havenga, Angelique A. C. Lemckert, Femke Hoeksema, Wilfried A.M. Bakker, Gert Gillissen
Publikováno v:
Vaccine
Highlights • A low-cost manufacturing process for a neonatal rotavirus vaccine was developed. • The formulation process developed resulted in a stable liquid vaccine at 2–8 °C. • No pretreatment of vaccinees with antacid needed before oral a
Publikováno v:
Lipids in Health and Disease, Vol 19, Iss 1, Pp 1-10 (2020)
Lipids in Health and Disease
Lipids in Health and Disease
Background Reduction in elevated serum cholesterol concentrations is important in the management of individuals at risk of atherosclerotic cardiovascular disease (ASCVD), such as myocardial infarction and thrombotic stroke. Although HMGCoA reductase
Autor:
Martina Kerscher, Michael H. Gold, Corey S. Maas, Steve Yoelin, Susanna Roll, John H Joseph, Tanja C. Fischer, Berthold Rzany, Welf Prager, Sabrina G. Fabi, Gudrun Klein
Publikováno v:
Journal of Drugs in Dermatology. 19:985-991
Background To further explore clinical trial results indicating increasing doses of botulinum toxin A prolong duration of effect, a 2-stage, phase 2, randomized, double-blind study investigated the duration of effect and safety of incobotulinumtoxinA
Autor:
Mary Z. Luo, Thomas R Murphy, Edward Kerwin, Jack Yongfeng Zhang, Donald P. Tashkin, George W. Bensch, Tony Marrs
Publikováno v:
Journal of Aerosol Medicine and Pulmonary Drug Delivery
Background: Two sequential single-dose crossover dose-ranging studies were performed to evaluate the clinical efficacy and safety profile of epinephrine hydrofluroalkane (HFA) metered-dose inhaler (MDI) formulation at various doses in subjects with a